Oct. 17, 2024
The American College of Radiology® (ACR®) and other medical specialty societies that use or perform interventional pain and spine procedures submitted a letter to five of the seven Medicare administrative contractors (MACs) their final local coverage determination (LCD) on Trigger Point Injections (TPI). Celerian Group Company Administrators, LLC, Noridian Healthcare Solutions, LLC, National Government Services, Inc., Palmetto GBA and Wisconsin Physicians Service Insurance Corporation deem ultrasound guidance for TPIs as investigational because of a lack of evidence of enhanced safety.

The specialty societies encourage these MACs to review new guidelines that support the use of ultrasound guidance for TPIs in specific anatomic locations. Without ultrasound guidance availability, diagnostic relevance is lost and the safety of certain TPI injections (e.g., anterior neck muscles, deep gluteal muscles, chest wall) are greatly reduced.

The ACR Contractor Advisory Committee (CAC) Network representatives relayed their concerns about this adverse LCD in March.

For more information or if you have questions, contact Alicia Blakey, ACR Principal Economic Policy Analyst.

Related ACR News

  • Make America Healthy Again

    President Trump released an Executive Order (EO) establishing the "Make America Healthy Again (MAHA) Commission,” Feb. 13 to be led by the new Department of Health and Human Services Secretary Robert F. Kennedy Jr.

    Read more
  • Scope of Practice Bills Introduced At State Legislative Level

    The American College of Radiology® (ACR®) is tracking more than 58 scope of practice bills across 22 states with more expected to be considered.

    Read more
  • ACR Others Challenge MAC Position on Minimally Invasive Arthrodesis of the Sacroiliac Joint

    The American College of Radiology® (ACR®) and other medical specialty societies that use or perform interventional pain and spine procedures told three of the seven Medicare Administrative Contractors (MACs) that implementation of a new policy as written could limit access to a safe, effective and durable treatment option, potentially exacerbating healthcare disparities among Medicare patients.

    Read more